Indivior PLC Scraps Dividend: Should You Sell And Buy AstraZeneca plc Or Shire PLC?

As Indivior PLC (LON:INDV) faces the threat of new competition, are AstraZeneca plc (LON:AZN) and Shire PLC (LON:SHP) better buys?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing in a company that only has one product is always risky, as shareholders in Indivior (LSE: INDV) discovered this morning. The group has announced that dividends will be suspended for the foreseeable future once the final dividend for 2015 has been paid.

Indivior shares were stable following the news, but have fallen by 44% from last summer’s high of 271p. Any hope of a rapid rebound look less likely now that the stock’s attractive 5% yield is gone.

In today’s article I’ll look more closely at Indivior’s 2015 results. Are the shares still a buy, or might you do better to invest in larger peers such as AstraZeneca (LSE: AZN) and Shire (LSE: SHP).

2015 good, 2016 bad?

Indivior was expected to report earnings per share of $0.31 and sales of $951m for 2015. The actual results were slightly better, with the firm generating $1,014m of sales and earnings of $0.32 per share.

An operating profit of $346m gave a healthy margin of 34%. Net debt fell to $174m, from $428m the year before. Given the firm’s post-tax profit of $228m, there doesn’t seem much reason to cancel the dividend.

However, Indivior’s net debt appears low because it has a large cash balance. Total borrowings are $605m, and the firm incurred $44m of interest costs last year. As generic competition increases, Indivior expects profits to fall by around 25% in 2016. Debt levels need to come down to maintain an acceptable ratio of debt to earnings.

Indivior also has a second problem. There are currently six new drug applications in the USA for generic alternatives to Suboxone Film, Indivior’s core product. Current generic competitors can’t use film (which dissolves on the tongue) to deliver the treatment, which is used to treat opioid addiction.

Indivior’s profit guidance for 2016 assumes that no generic film products will enter the market. If a generic film application is successful, then Indivior could see a much sharper fall in sales and profits.

Cutting the dividend makes sense, but it could be a few years before shareholders see the benefits of Indivior’s pipeline of new products. Are the shares a sell until the outlook improves?

Bigger = better?

AstraZeneca has its own problems with generic competition. The firm’s profits are expected to flatline in 2017, but are forecast to be 50% lower than in 2011.

However, AstraZeneca’s much larger portfolio and its pipeline of new products means that shareholders haven’t lost out on the firm’s attractive 4.5% dividend yield. The potential for longer-term growth remains significant, in my view.

Trading on 15 times forecast earnings, AstraZeneca looks more attractive to me than Indivior, whose shares are now cheap for a reason.

I’m less keen on Shire. The firm is in the process of completing the $32bn acquisition of Baxalta. This is a deal that should provide some attractive new products but will also leave Shire with net debt of around $25bn. Although Shire trades on an apparently cheap 2017 forecast P/E of 11, when debt is factored-into the firm’s valuation the shares look fully-priced to me.

I’d also like to see some evidence that Shire can diversify away from a high level of dependence on its flagship Vyvanse ADHD treatment, which accounted for 28% of the firm’s sales last year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »